Last reviewed · How we verify
Gilotrif
At a glance
| Generic name | Gilotrif |
|---|---|
| Also known as | Afatinib |
| Sponsor | Seoul St. Mary's Hospital |
| Target | Citron Rho-interacting kinase, Adenosine kinase, Casein kinase I isoform epsilon |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
- Non-small cell lung cancer, positive for epidermal growth factor receptor expression
Common side effects
Key clinical trials
- A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors (Phase 1)
- A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (Phase 1)
- The Master Protocol for Biomarker-Integrated Umbrella Trial in Advanced Gastric Cancer (NA)
- LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Tre (Phase 2)
- Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study. (Phase 2)
- A Prospective Randomized Controlled Trial Comparing Low-Dose Radiotherapy Combined With Targeted Therapy and Immunotherapy Versus Targeted Therapy and Immunotherapy Alone as Neoadjuvant Therapy in Pat (Phase 2)
- A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients (Phase 3)
- Efficacy and Safety of Precision Therapy in Refractory Tumor (Long March Pathway) (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gilotrif CI brief — competitive landscape report
- Gilotrif updates RSS · CI watch RSS
- Seoul St. Mary's Hospital portfolio CI